2-amino-5-phosphonovalerate has been researched along with Anochlesia in 17 studies
2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.
Excerpt | Relevance | Reference |
---|---|---|
"The present study examined whether the catalepsy induced by L-NOARG (ip) can be influenced by collicular glutamatergic mechanisms and if a NO-dependent neural substrate into the IC plays a role in this immobility state." | 1.38 | L-NOARG-induced catalepsy can be influenced by glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus. ( Barbosa-Silva, R; Iacopucci, AP; Mello, RO; Melo-Thomas, L, 2012) |
"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0." | 1.36 | Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy. ( Brandão, ML; Coimbra, NC; Ferrari, EA; Francisco, A; Maisonnette, SS; Medeiros, P; Mello, RO; Melo, LL; Santos, P, 2010) |
"These findings suggest that, while the catalepsy resulting from DA receptor blockade by haloperidol originates mainly from the VM, the expression of this phenomenon depends on an intact glutamatergic transmission within the dorsorostral CP." | 1.29 | Distinct sites of dopaminergic and glutamatergic regulation of haloperidol-induced catalepsy within the rat caudate-putamen. ( Kawano, K; Miyagishi, T; Ono, T; Yoshida, Y, 1994) |
"Therefore, the THC-induced catalepsy model may be useful for distinguishing between both classes of NMDA receptor antagonists." | 1.29 | Competitive NMDA antagonists enhance the catalepsy induced by delta 9-tetrahydrocannabinol in mice. ( Hasegawa, T; Kameyama, T; Kinoshita, H; Nabeshima, T; Yamamoto, I, 1994) |
"The reserpine-induced catalepsy was attenuated by CGP 37849." | 1.29 | Some central effects of CGP 37849 and CGP 39551, the competitive NMDA receptor antagonists: potential antiparkinsonian activity. ( Maj, J; Rogóz, Z; Skuza, G, 1993) |
"This type of 'catalepsy' is clearly different from the state which is produced by the administration of neuroleptics, e." | 1.29 | Morphine-induced catalepsy is augmented by NMDA receptor antagonists, but is partially attenuated by an AMPA receptor antagonist. ( Schmidt, WJ; Tzschentke, TM, 1996) |
"The potentiation of methadone-induced catalepsy in decorticated rats was mimicked in naive rats by intrastriatal (i." | 1.27 | Enhancement of opioid cataleptic response by cortical frontal deafferentation or intrastriatal injection of NMDA-receptor antagonists. ( Consolo, S; Forloni, G; Ladinsky, H; Palazzi, E, 1988) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (23.53) | 18.7374 |
1990's | 11 (64.71) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (11.76) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Melo, LL | 1 |
Santos, P | 1 |
Medeiros, P | 1 |
Mello, RO | 2 |
Ferrari, EA | 1 |
Brandão, ML | 1 |
Maisonnette, SS | 1 |
Francisco, A | 1 |
Coimbra, NC | 1 |
Iacopucci, AP | 1 |
Barbosa-Silva, R | 1 |
Melo-Thomas, L | 1 |
Hauber, W | 3 |
Münkle, M | 2 |
Yoshida, Y | 2 |
Ono, T | 2 |
Kawano, K | 1 |
Miyagishi, T | 2 |
Waldenmeier, MT | 1 |
Kinoshita, H | 1 |
Hasegawa, T | 1 |
Kameyama, T | 1 |
Yamamoto, I | 1 |
Nabeshima, T | 1 |
Maj, J | 1 |
Skuza, G | 1 |
Rogóz, Z | 1 |
Tzschentke, TM | 1 |
Schmidt, WJ | 2 |
Kretschmer, BD | 1 |
Zadow, B | 1 |
Volz, TL | 1 |
Volz, L | 1 |
Sagratella, S | 1 |
Scotti de Carolis, A | 1 |
Pèzzola, A | 1 |
Popoli, P | 1 |
Urbańska, E | 1 |
Ikonomidou, C | 1 |
Sieklucka, M | 1 |
Turski, WA | 1 |
Millan, MH | 1 |
Wardley-Smith, B | 1 |
Halsey, MJ | 1 |
Meldrum, BS | 1 |
Koek, W | 2 |
Kleer, E | 1 |
Mudar, PJ | 1 |
Woods, JH | 2 |
Ornstein, P | 1 |
Consolo, S | 1 |
Forloni, G | 1 |
Ladinsky, H | 1 |
Palazzi, E | 1 |
Kizu, A | 1 |
Fukushima, R | 1 |
17 other studies available for 2-amino-5-phosphonovalerate and Anochlesia
Article | Year |
---|---|
Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.
Topics: 2-Amino-5-phosphonovalerate; Animals; Catalepsy; Dizocilpine Maleate; Dose-Response Relationship, Dr | 2010 |
L-NOARG-induced catalepsy can be influenced by glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus.
Topics: 2-Amino-5-phosphonovalerate; Animals; Catalepsy; Dose-Response Relationship, Drug; Drug Administrati | 2012 |
Stimulation of adenosine A2a receptors in the rat striatum induces catalepsy that is reversed by antagonists of N-methyl-D-aspartate receptors.
Topics: 2-Amino-5-phosphonovalerate; Adenosine; Animals; Anticonvulsants; Catalepsy; Corpus Striatum; Dizoci | 1995 |
Distinct sites of dopaminergic and glutamatergic regulation of haloperidol-induced catalepsy within the rat caudate-putamen.
Topics: 2-Amino-5-phosphonovalerate; Animals; Behavior, Animal; Catalepsy; Caudate Nucleus; Dopamine; Glutam | 1994 |
The AMPA receptor antagonist GYKI 52466 reverses the anti-cataleptic effects of the competitive NMDA receptor antagonist CGP 37849.
Topics: 2-Amino-5-phosphonovalerate; Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Catalep | 1994 |
Competitive NMDA antagonists enhance the catalepsy induced by delta 9-tetrahydrocannabinol in mice.
Topics: 2-Amino-5-phosphonovalerate; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Amantadine; | 1994 |
Some central effects of CGP 37849 and CGP 39551, the competitive NMDA receptor antagonists: potential antiparkinsonian activity.
Topics: 2-Amino-5-phosphonovalerate; alpha-Methyltyrosine; Animals; Antiparkinson Agents; Antipsychotic Agen | 1993 |
Morphine-induced catalepsy is augmented by NMDA receptor antagonists, but is partially attenuated by an AMPA receptor antagonist.
Topics: 2-Amino-5-phosphonovalerate; Animals; Anti-Anxiety Agents; Benzodiazepines; Catalepsy; Dizocilpine M | 1996 |
The adenosine receptor antagonist theophylline induces a monoamine-dependent increase of the anticataleptic effects of NMDA receptor antagonists.
Topics: 2-Amino-5-phosphonovalerate; Animals; Catalepsy; Dizocilpine Maleate; Dopamine; gamma-Aminobutyric A | 1996 |
The contribution of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the expression of behavior.
Topics: 2-Amino-5-phosphonovalerate; Animals; Behavior, Animal; Binding Sites; Catalepsy; Cycloserine; Dizoc | 1992 |
Behavioural and electoencephalographic interactions between haloperidol and PCP/sigma ligands in the rat.
Topics: 2-Amino-5-phosphonovalerate; Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; | 1991 |
Aminooxyacetic acid produces excitotoxic lesions in the rat striatum.
Topics: 2-Amino-5-phosphonovalerate; Amino Acids; Aminooxyacetic Acid; Animals; Behavior, Animal; Catalepsy; | 1991 |
Studies on the role of the NMDA receptor in the substantia nigra pars reticulata and entopeduncular nucleus in the development of the high pressure neurological syndrome in rats.
Topics: 2-Amino-5-phosphonovalerate; Amino Acids; Animals; Aspartic Acid; Atmospheric Pressure; Catalepsy; G | 1989 |
Phencyclidine-like catalepsy induced by the excitatory amino acid antagonist DL-2-amino-5-phosphonovalerate.
Topics: 2-Amino-5-phosphonovalerate; Animals; Catalepsy; Columbidae; Injections, Intraventricular; Phencycli | 1986 |
Phencyclidine-like behavioral effects in pigeons induced by systemic administration of the excitatory amino acid antagonist, 2-amino-5-phosphonovalerate.
Topics: 2-Amino-5-phosphonovalerate; Animals; Aspartic Acid; Behavior, Animal; Catalepsy; Columbidae; Dose-R | 1986 |
Enhancement of opioid cataleptic response by cortical frontal deafferentation or intrastriatal injection of NMDA-receptor antagonists.
Topics: 2-Amino-5-phosphonovalerate; Amino Acids; Animals; Anticonvulsants; Catalepsy; Cerebral Cortex; Cere | 1988 |
Striatal N-methyl-D-aspartate receptors in haloperidol-induced catalepsy.
Topics: Animals; Catalepsy; Cerebral Cortex; Corpus Striatum; Excitatory Amino Acid Antagonists; Glutamates; | 1991 |